Last reviewed · How we verify
Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days Per Week for the Treatment of Actinic Keratoses in Immunosuppressed Organ Transplant Recipients.
The purpose of the study is to compare effectiveness and safety of multiple applications of imiquimod 5% cream and vehicle cream in graft recipients suffering from actinic keratosis.
Details
| Lead sponsor | MEDA Pharma GmbH & Co. KG |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 45 |
| Start date | 2002-11 |
| Completion | 2005-09 |
Conditions
- Actinic Keratosis
Interventions
- Imiquimod 5 % Cream
Primary outcomes
- Primary outcome of the study is to compare imiquimod 5% cream and vehicle cream with respect to safety assessments in graft recipients.